Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)

Imperial College Healthcare NHS Trust

Status and phase

Active, not recruiting

Phase 4

Conditions

Carotid Artery Stenosis

Treatments

Drug: Evolocumab Auto-Injector [Repatha]

Drug: Placebo Auto-Injector

Study type

Interventional

Funder types

Other

Identifiers

NCT03931161

EVOCAR-1

Details and patient eligibility

About

This is a phase IV, randomised, placebo-controlled, double-blind, parallel group study to determine the effect of Evolocumab treatment on carotid plaque morphology and composition in asymptomatic patients with >50% carotid artery stenosis.

Full description

In this study patients will be randomised in a 1:1 ratio to receive Evolocumab 140 mg every two weeks or matching placebo, to be administered for 12 months. After 12 months of treatment, patients will remain in follow-up for a further 12 months.

High resolution magnetic resonance imaging (MRI) will be used to serially monitor the impact of Evolocumab on carotid plaque morphology and composition in patients with significant carotid stenosis who do not meet clinical criteria for carotid endarterectomy. This approach will reveal if clinically beneficial plaque regression occurs, without requiring the large patient cohorts or long follow-up needed for cardiovascular outcome trials.

Results from this study will establish whether treatment with Evolocumab is likely to be beneficial to patients with asymptomatic carotid stenosis.

Enrollment

33 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18 years
Sufficient English language ability to adequately understand the study
Able to give informed consent
Significant carotid artery plaque with 50-70% stenosis on ultrasound or MRI performed prior to screening
Significant asymptomatic carotid artery plaque with >70% stenosis on ultrasound or MRI performed prior to screening, but carotid endarterectomy or carotid artery stenting has been deemed unsuitable by multidisciplinary team during routine clinical care
Lipid-rich necrotic core (LRNC) on baseline MRI scan
Adequate image quality for MRI analysis.
LDL-C ≥2.6 mmol/L (100 mg/dL)
On stable dose of maximally-tolerated lipid-lowering therapy in accordance with UK national clinical guidelines (NICE CG18120) for ≥2 months prior to screening. Acceptable non-statin lipid-lowering medications include ezetimibe or a fibrate.

Exclusion criteria

Any medical condition which, in the opinion of the investigators, would present an unacceptable risk to the participant if they were to take part in the trial, or prevent them from following the trial protocol
Current or previous treatment with a PCSK9 inhibitor
Eligible for PCSK9 inhibitor treatment under current NICE guidelines
Contra-indication to or inability to use Evolocumab treatment, including:
- Sensitivity to Evolocumab or any associated excipients
- Unable to tolerate or perform self-administration of Evolocumab by auto-injector
- Lack of suitable refrigerated storage
Contra-indication to or inability to tolerate MRI
Estimated glomerular filtration rate (eGFR) ≤45 mL/min/1.73 m2 prior to MRI scan
Pregnancy or breast-feeding
Women of childbearing potential who are unwilling or unable to use a highly effective method of contraception